Two pharmaceutical giants are currently locked in a high-stakes battle over a 100 billion-dollar obesity drug market, and the weapon of choice is no longer just a molecule. It is a federal lawsuit.
Recently, Novo Nordisk filed a lawsuit against Eli Lilly in the United States District Court for the District of New Jersey, alleging false advertising under the Lanham Act. This is not a dispute about clinical trial methodology alone. It is a battle for market share that has expanded from the laboratory to the courtroom. When direct clinical comparisons become a central marketing feature, legal strategy becomes inseparable from commercial strategy.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
